Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Safety and reactogenicity of the recombinant zoster vaccine after allogeneic hematopoietic cell transplantation

12 Mar 2021

Abstract excerpt

Allogeneic hematopoietic cell transplantation (HCT) recipients are at increased risk for varicella zoster virus (VZV) reactivation and associated complications. A nonlive adjuvanted recombinant zoster vaccine (RZV) has been developed to prevent herpes zoster (HZ), but there are no recommendations for use in this population. In this single-center prospective observational cohort study, we assessed the safety and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bartonella species infections research
Share to Herpesvirus Infections and Treatments
Share to Poxvirus research and outbreaks

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33710336
DOI: 10.1182/bloodadvances.2020003749

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety and reactogenicity of the recombinant zoster vaccine after allogeneic hematopoietic cell transplantationPMID 33710336Read ↗

Efficacy and side effects of the Herpes Zoster vaccine in immunocompromised individuals – a systematic reviewSemantic proximity Read ↗

Recombinant Zoster Vaccine Uptake and Risk of Flares Among Older Adults With Immune‐Mediated Inflammatory Diseases in the USSemantic proximity Read ↗

Real-world Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in ≥50-year-old Adults With Autoimmune DiseasesSemantic proximity Read ↗

Clinical-grade varicella zoster virus-specific T cells produced for adoptive immunotherapy in hemopoietic stem cell transplant recipients.Semantic proximity Read ↗

SARS-CoV-2 Vaccine Non-response among Hematopoietic Stem Cell Transplant Patients: A Systematic Review and Meta-analysisSemantic proximity Read ↗

Sequential Data-Mining for Adverse Events After Recombinant Herpes Zoster Vaccination Using the Tree-Based Scan StatisticSemantic proximity Read ↗

Immunogenicity and safety of the BNT162b2 mRNA COVID‐19 vaccine in haematopoietic stem cell transplantation recipientsSemantic proximity Read ↗

Immune response to the recombinant herpes zoster vaccine in people living with HIV over 50 years of age compared to non-HIV age-/gender-matched controls (SHINGR’HIV): a multicenter, international, non-randomized clinical trial study protocolSemantic proximity Read ↗

Cell-Mediated Immune Responses After Administration of the Live or the Recombinant Zoster Vaccine: 5-Year PersistenceSemantic proximity Read ↗

Association Between Immunogenicity and Reactogenicity: A Post Hoc Analysis of 2 Phase 3 Studies With the Adjuvanted Recombinant Zoster VaccineSemantic proximity Read ↗

Epidemiology and clinical profile of herpes zoster in the varicella vaccine era: A case series studySemantic proximity Read ↗

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March−June 2021, EnglandSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.